Literature DB >> 15254019

Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use.

Kyle P Chiang1, Alexandra L Gerber, Jack C Sipe, Benjamin F Cravatt.   

Abstract

Fatty acid amide hydrolase (FAAH) inactivates the endogenous cannabinoid (endocannabinoid) anandamide and related lipid transmitters in vivo. A single nucleotide polymorphism (SNP) in the human FAAH gene (385C to A) has recently been described that, in homozygous form, is over-represented in subjects with problem drug use. This SNP, which converts a conserved proline residue in FAAH to threonine (P129T), suggests a potential role for the FAAH-endocannabinoid system in regulating addictive behavior. Nonetheless, the impact of the 385A mutation on the biochemical and cellular function of FAAH remains unknown. Here, we report that T-lymphocytes isolated from patients homozygous for the P129T-FAAH variant express less than half of the FAAH protein and activity observed in wild-type (WT) lymphocytes. Transfected COS-7 cells also expressed significantly lower levels of P129T-FAAH compared with WT-FAAH, indicating that the aberrant expression of the former protein is not a cell type-specific phenomenon. A comparison of the transcription/translation efficiencies and cellular stabilities of WT- and P129T-FAAH proteins revealed that the reduced expression of the mutant enzyme is due to a post-translational mechanism that precedes productive folding. These findings indicate that the natural 385A SNP in the human FAAH gene produces a mutant enzyme with reduced cellular stability, thus fortifying a potential link between functional abnormalities in the endocannabinoid system and drug abuse and dependence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254019     DOI: 10.1093/hmg/ddh216

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  110 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.

Authors:  O Gunduz-Cinar; K P MacPherson; R Cinar; J Gamble-George; K Sugden; B Williams; G Godlewski; T S Ramikie; A X Gorka; S O Alapafuja; S P Nikas; A Makriyannis; R Poulton; S Patel; A R Hariri; A Caspi; T E Moffitt; G Kunos; A Holmes
Journal:  Mol Psychiatry       Date:  2012-06-12       Impact factor: 15.992

Review 3.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

4.  Genetic variation in FAAH is associated with cannabis use disorders in a young adult sample of Mexican Americans.

Authors:  Whitney E Melroy-Greif; Kirk C Wilhelmsen; Cindy L Ehlers
Journal:  Drug Alcohol Depend       Date:  2016-06-25       Impact factor: 4.492

Review 5.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

Review 6.  Amygdala FAAH and anandamide: mediating protection and recovery from stress.

Authors:  Ozge Gunduz-Cinar; Matthew N Hill; Bruce S McEwen; Andrew Holmes
Journal:  Trends Pharmacol Sci       Date:  2013-10-25       Impact factor: 14.819

Review 7.  Understanding placebo and nocebo responses for pain management.

Authors:  Luana Colloca; Christian Grillon
Journal:  Curr Pain Headache Rep       Date:  2014-06

8.  Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomy.

Authors:  Jacek Biesiada; Vidya Chidambaran; Michael Wagner; Xue Zhang; Lisa J Martin; Jaroslaw Meller; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

Review 9.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

10.  Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.

Authors:  Francesca M Filbey; Joseph P Schacht; Ursula S Myers; Robert S Chavez; Kent E Hutchison
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.